Atrial Flutter: Mechanisms, ECG Recognition and Management

Definition and Pathophysiology

Atrial flutter is defined by a macroreentrant atrial circuit, which manifests on the electrocardiogram (ECG) as organized, continuous atrial electrical activity. This activity most commonly presents as a characteristic saw-tooth pattern at rates typically exceeding 200 beats per minute. While ECG appearances with flutter-like patterns are predominantly caused by macroreentrant circuits, microreentry remains a possible alternative mechanism. Conversely, certain macroreentrant atrial tachycardias (MRATs) that traverse protected anatomical areas may display a focal atrial tachycardia pattern on the ECG, characterized by discrete P waves separated by an isoelectric baseline.

The most likely mechanism underlying typical atrial flutter is reentry. In the common form of typical atrial flutter, the reentrant circuit is confined to the right atrium and travels in a counterclockwise direction. The activation wavefront propagates in a craniocaudal direction down the right atrial free wall, traverses the cavotricuspid isthmus (CTI) at the inferior boundary, and ascends in a caudocranial direction along the interatrial septum. The left atrium is activated passively. The upper boundary of this circuit may be located either anterior or posterior to the superior vena cava. A critical area of slow conduction is consistently located in the posterolateral to posteromedial inferior region of the right atrium. This circuit also relies on a central area of block, which encompasses both an anatomical barrier (the inferior vena cava) and a functional component. When the direction of the reentrant circuit is reversed, propagating in a clockwise direction, it results in a distinct ECG pattern designated as typical reverse flutter.

Typical atr flutter exhibits strong reproducible anatomical dependence, which explains the high morphological reproducibility of its ECG pattern. However, this well-recognized pattern can be significantly altered when atrial activation is modified by cardiac surgery involving atrial tissue, extensive prior radiofrequency ablation, advanced atrial disease, or the use of antiarrhythmic drugs. In such clinical scenarios, an atypical ECG presentation does not definitively exclude a typical flutter circuit utilizing the CTI.

Atrial flutter is broadly categorized into two types: CTI-dependent flutter and non-CTI-dependent (atypical) flutter. The terms non-CTI-dependent MRAT and atypical flutter are used interchangeably to describe flutter waves on the ECG that do not suggest a typical circuit. A diagnostic pitfall arises because typical circuits occurring in diseased atria—most frequently following surgery or extensive ablation, or under the influence of antiarrhythmic drugs—can produce atypical ECG patterns. Conversely, upper-loop reentry can mimic a typical flutter ECG pattern without being dependent on the CTI. Consequently, true atypical flutter is considered a post hoc diagnosis, confirmed only after the circuit has been fully outlined and dependence on the CTI has been definitively ruled out.

Typical flutter is closely related to atrial fibrillation (AF) in clinical practice. Both arrhythmias are associated with similar clinical settings and frequently coexist in the same patient population. AF can act as a trigger for atrial flutter, and the development of AF is common following the successful ablation of typical flutter. Furthermore, typical flutter frequently emerges in patients undergoing pharmacological treatment for AF with class IC drugs or amiodarone. In these instances, the flutter rate may be reduced to less than 200 beats per minute, which paradoxically facilitates 1:1 atrioventricular (AV) conduction.

Clinical Presentation and Symptoms

Patients with atrial flutter typically present with symptoms related to high ventricular rates and the loss of the atrial kick. The rapid ventricular response can lead to a reversible depression of systolic function. If the tachycardia persists, it is not unusual for patients to develop tachycardiomyopathy (TCM).

In specific clinical contexts, such as cardiac amyloidosis (CA), both tachycardia and bradycardia are poorly tolerated due to restrictive hemodynamics. In this patient group, maintaining sinus rhythm and preserving the atrial contribution to ventricular filling may be less critical, as many individuals possess significantly reduced atrial mechanical function. For these patients, regularization and slowing of the heart rate likely provide equal or greater clinical benefit than maintaining sinus rhythm.

Evaluation and Physical Examination

The physical examination in atrial flutter may reveal findings associated with AV dissociation or variable conduction. The intensity of the first heart sound (S1) can vary as the PR interval changes. An inconsistent relationship between the a and v waves may be observed in the jugular venous pulse. Intermittent large cannon a waves can appear in the jugular venous pulse when atrial and ventricular contractions occur simultaneously. The second heart sound (S2) may split normally or paradoxically, depending on the manner of ventricular activation. A premature beat representing ventricular capture can interrupt a regular heart rhythm. When the ventricular rate exceeds the atrial rate, a cyclic increase in the intensity of S1 is produced as the PR interval shortens, culminating in a very loud sound known as the bruit de canon. This intense sound is followed by a sudden reduction in S1 intensity and the appearance of giant a waves as the PR interval shortens and the P waves march through the cardiac cycle.

Diagnostics

Electrocardiography

The surface ECG is fundamental to the diagnosis and classification of atrial flutter. In counterclockwise (typical common) flutter, the reentrant circuit generates regular atrial activation at a rate of 250 to 330 beats per minute. This produces the classic saw-tooth pattern, characterized by negative flutter waves in the inferior leads and positive waves in lead V1. In clockwise (typical reverse) flutter, the flutter waves in the inferior leads appear positive and broad, and are frequently bimodal and negative in lead V1.

When a patient presents with 2:1 AV block, the underlying flutter waves may not be immediately obvious on the surface ECG. In such situations, the administration of intravenous adenosine can increase the degree of AV block, thereby unmasking the typical ECG pattern. However, adenosine carries a risk of producing a rebound increase in AV conduction to 1:1 and may also precipitate AF. Therefore, it should only be utilized when deemed strictly necessary for diagnostic purposes and when appropriate resuscitation equipment is readily available.

Electrophysiology and Electroanatomic Mapping

Electroanatomic mapping is essential for delineating atrial flutter circuits, particularly for non-CTI-dependent flutters which require more extensive mapping than CTI-dependent flutter. During electrophysiologic study, electroanatomic maps reveal the electrical activation pattern, displaying a color-coded sequence where "early meets late" (typically red meeting purple) to indicate the reentrant circuit. For example, a typical counterclockwise CTI-dependent flutter with a cycle length of 260 ms can be visualized and subsequently terminated by delivering radiofrequency ablation lesions across the CTI.

Atypical flutter circuits can be complex and are often identified through electroanatomic mapping. Examples include:

• Roof-dependent flutter: A circuit rotating around the right-sided pulmonary veins in a counterclockwise direction. Ablation across the atrial roof between the right and left superior pulmonary veins can terminate this circuit.

• Mitral isthmus-dependent flutter: A circuit rotating around the mitral annulus. The ECG morphology has poor sensitivity and specificity for localizing this circuit, particularly in the context of structural heart disease or prior ablation.

• Dual-loop reentry: Patients with advanced atrial remodeling and prior AF ablation may exhibit simultaneous reentrant circuits. For instance, one circuit may rotate around the right pulmonary veins while another rotates around the left pulmonary veins and the left atrial appendage. Both may be roof-dependent and terminated by a linear ablation line across the left atrial roof. Dual-loop reentry can also occur in patients with prior atrial septal defect (ASD) repair, where one loop encircles the tricuspid annulus (typical counterclockwise flutter) and another encircles the superior vena cava and an atriotomy scar (upper loop reentry). Ablation of the CTI may interrupt the tricuspid annulus loop without altering the cycle length if the upper loop circuit persists.

• Epicardial circuits: Epicardial structures can sustain macroreentry by bypassing endocardial ablation lines. An epicardial muscle bundle within the CTI can allow activation to jump across a line of block. Similarly, Bachmann's bundle can facilitate epicardial conduction across an anterior ablation line, and the vein of Marshall can bypass a mitral isthmus ablation line. The septopulmonary bundle can also allow a circuit to jump across posterior left atrial ablation lines.

Biomarkers and Laboratory Findings

The source material does not cover specific biomarkers or routine laboratory findings for atrial flutter.

Treatment and Management

The management of atrial flutter follows a stepwise approach encompassing anticoagulation, acute rate or rhythm control, and long-term strategies to maintain sinus rhythm.

Acute Management

Acute therapy involves both rate and rhythm control strategies. The first step should be rate control when the ventricular rate is high, though achieving adequate rate control in atrial flutter can be particularly challenging. Even combinations of AV nodal-blocking agents (digoxin, beta-blockers, and calcium channel blockers) may fail, necessitating cardioversion.

• Rate Control: In hemodynamically stable patients, rate control is achieved using oral or intravenous beta-blockers, diltiazem, or verapamil. Intravenous amiodarone is a useful alternative for acute rate control, particularly in critically ill patients or those with heart failure, when beta-blockers are contraindicated or ineffective. Digitalis may also aid in slowing the ventricular rate, particularly in the setting of ventricular dysfunction following acute myocardial infarction.

• Rhythm Control: For hemodynamically unstable patients, synchronized electrical cardioversion is indicated. Low-energy electrical cardioversion is highly effective for atrial flutter and requires less energy compared to AF. It can also be employed as a first-line approach in stable patients due to its high efficacy.

• Pharmacological Cardioversion: Pure class III antiarrhythmic drugs, such as intravenous ibutilide and intravenous or oral dofetilide, are generally effective in interrupting atrial flutter. These agents carry a potential risk for ventricular proarrhythmia, which is increased in patients with impaired left ventricular function; therefore, they should be administered in a hospital setting with careful monitoring. Class IA and IC drugs have little to no acute effect. Intravenous amiodarone may not be highly effective acutely for restoring sinus rhythm but is useful for ventricular rate control.

• Atrial Pacing: When atrial electrodes are in place (such as in patients with temporary pacing wires or permanent cardiac devices), high-rate atrial stimulation can be used to convert flutter, sometimes transitioning through AF, which may subsequently allow for better ventricular rate control. Atrial pacing can also be performed using percutaneous endocardial electrodes or from the oesophagus, a technique mostly utilized in paediatrics. Pre-treatment with procainamide may facilitate conversion by atrial pacing.

Chronic Therapy and Catheter Ablation

Catheter ablation represents the cornerstone of long-term management and is increasingly favored as first-line therapy due to its high success rate, low complication risk, and low recurrence rates. It may be considered after a first episode or in patients with recurrent or persistent episodes, and is particularly indicated in patients who develop TCM.

• CTI-Dependent Flutter Ablation: Ablation is performed across the CTI from the tricuspid annulus to the eustachian ridge at the anterior margin of the inferior vena cava. The procedural endpoint is the demonstration of bidirectional conduction block across the ablation line using standard electrophysiology mapping techniques. The acute success rate exceeds 97%, the recurrence rate is approximately 5% to 10%, and the risk for serious adverse events is under 1%.

• Non-CTI-Dependent Flutter Ablation: Success rates for atypical flutter are more variable and depend on the underlying cardiac pathology. In simple forms of scar-related flutter (e.g., post-ASD repair or mitral valve repair), success rates approach 90%. However, the need for multiple procedures is more common (>20% to 30%) due to the frequent presence of multiple circuits, and the late incidence of AF is high (>30% at 2 years). In complex surgically repaired congenital heart disease (e.g., Fontan or Mustard/Senning repairs), acute success rates are lower, multiple procedures are frequently required, and long-term recurrences are common. In the era of AF ablation, atypical flutter occurs in up to 20% of patients post-procedure, particularly those who underwent persistent AF ablation with extensive or linear lesions.

• Pharmacological Rhythm Control: For patients in whom catheter ablation is contraindicated, not feasible, or previously failed, antiarrhythmic drugs may be utilized to maintain sinus rhythm. Options include sotalol, dofetilide, or amiodarone, with amiodarone preferred in the presence of significant left ventricular dysfunction. Antiarrhythmic drug therapy is associated with a high rate of recurrences (>70%).

• AV Node Ablation: If drug therapy is unsuccessful, poorly tolerated, and catheter ablation fails or is not feasible in the setting of persistent fast ventricular rates, AV node ablation followed by pacing (usually biventricular or His-bundle pacing) can be considered.

Anticoagulation

Anticoagulation therapy plays a pivotal role in preventing thromboembolic events. Management of atrial flutter generally follows the same recommendations as for AF. Decisions regarding anticoagulation should be dictated by the CHA2DS2-VASc score and bleeding risk assessment rather than the apparent achievement of rhythm control. Anticoagulation is crucial before considering conversion to sinus rhythm, unless electrical cardioversion is urgently warranted for hemodynamic instability or severe symptoms. Data on pre-cardioversion anticoagulation specifically for atrial flutter are lacking, but patients should be treated similarly to those with AF. Heparins, vitamin K antagonists, or direct-acting oral anticoagulants are all effective and should be considered as indefinite therapy with minimal interruption.

In specific populations such as those with cardiac amyloidosis, the stroke risk is exceedingly high due to blood stasis, elevated pressures, and atrial amyloid deposition. Left atrial appendage thrombosis has been observed even in the presence of normal sinus rhythm and after therapeutic anticoagulation, underscoring the recommendation to perform transesophageal echocardiography prior to attempting restoration of sinus rhythm.

Drugs, Doses, and Practical Considerations

Pharmacological management requires careful consideration of drug-specific risks and contraindications.

Guideline Recommendations

Guideline-directed therapy for atrial flutter incorporates specific classes of recommendation (COR) and levels of evidence (LOE) to guide clinical decision-making.

• Rhythm Control: Oral dofetilide or intravenous ibutilide are recommended for rhythm control. Rapid atrial pacing is also recommended in patients with temporary pacing wires or permanent cardiac devices in situ (COR I, LOE B-R; COR IIa, LOE B). Elective synchronized cardioversion is recommended for rhythm control, and sinus rhythm can be maintained with amiodarone, dofetilide, sotalol, flecainide, or propafenone.

• Rate Control: Oral beta-blockers, diltiazem, or verapamil are recommended for rate control (COR I, LOE C-LD; COR IIa, LOE C). Intravenous amiodarone is useful for acute rate control when beta-blockers are contraindicated or ineffective.

• Avoidance of Class IC Agents: Propafenone or flecainide should not be used for acute management because of the risk for atrial rate slowing allowing 1:1 AV conduction (COR III, LOE B).

• Anticoagulation: Antithrombotic therapy should be prescribed according to recommendations for patients with AF (COR I, LOE B-NR).

• Catheter Ablation of the CTI: Recommended for atrial flutter that is symptomatic or refractory to pharmacologic rate control (COR I, LOE B-R; COR Ia, LOE B). It is also recommended for persistent atrial flutter or flutter associated with depressed left ventricular systolic function (COR I, LOE B). CTI-dependent flutter resulting from the treatment of AF with flecainide, propafenone, or amiodarone carries a COR IIa, LOE B-NR recommendation. Patients undergoing AF ablation who have documented clinical or induced CTI-dependent atrial flutter also fall under COR IIa, LOE C-LD.

• Catheter Ablation of Non-CTI Flutters: Recommended for recurrent flutter after failure of at least one antiarrhythmic agent (COR I, LOE C-LD; COR I, LOE B) or as primary therapy (COR IIa, LOE C-LD).

• AV Nodal Ablation: Should be considered if medications or catheter ablation fail and tachycardia is persistent with fast ventricular rates (COR IIa, LOE C).

Prognosis and Follow-up

The prognosis of atrial flutter is closely tied to the development of tachycardiomyopathy and the high coexistence rate with atrial fibrillation. While catheter ablation of the CTI yields acute success exceeding 97% with recurrence rates of only 5% to 10%, up to half of the patients undergoing successful CTI ablation will subsequently develop atrial arrhythmias, with AF being the most common.

In patients undergoing ablation for atypical flutter, the long-term freedom from AF is high when control can be achieved, though the requirement for multiple procedures is common (>20% to 30%). The late incidence of AF in this cohort remains high (>30% at 2 years). In complex congenital heart disease populations, ablation serves as an effective palliative procedure, but long-term recurrences are common due to extensive atrial surgery and underlying anatomic abnormalities.

Postablation anticoagulation remains a subject of controversy, contingent upon the likelihood of the patient developing AF. Patients with a high-risk thromboembolic profile should continue anticoagulation, whereas those with a low-risk profile may be monitored off anticoagulation with clinical follow-up and arrhythmia monitoring. Anticoagulation may be considered for patients with high-risk features for the development of AF (COR 2b). Prophylactic CTI ablation may not be beneficial in patients with pre-existing AF, though treating atrial flutter with pulmonary vein isolation as first-line therapy has been suggested to prevent recurrent atrial flutter and reduce the risk of new-onset AF.